Close Menu

NEW YORK — Chinese molecular diagnostics firm AmoyDx said on Monday that it has partnered with Eisai on the development and registration of companion diagnostic tests.

Specific terms of the deal were not disclosed.

"We have been developing highly effective diagnostic solutions to guide treatment decisions of clinical precision oncology based on various technical platforms," AmoyDx Founder and CEO Li-mou Zheng said in a statement. "We are happy to have the opportunity of working together with Eisai on emerging valuable targets."

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

In a cartoon, Vox explores the lack of women among this year's winners of the Nobel Prize.

Science reports a new US defense bill would establish two groups aimed at combating foreign influence on research. 

Nature Biotechnology discusses promising early results from two clinical trials of CRISPR-based therapy for β-thalassemia and sickle cell disease.

In Cell this week: analysis of tissue clones, metagenomic studies of ocean water samples, and more.

Dec
19
Sponsored by
Qiagen

This webinar will provide a first-hand look at how a clinical lab evolved its tumor profiling workflow from a targeted panel approach toward comprehensive genomic profiling.  

Jan
28
Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.